This suggests markedly lower NAGS and CPS1 expression in glioblastoma multiforme, glioma, lung adenocarcinoma, stomach adenocarcinoma, and stomach and esophageal carcinoma than in the liver and small intestine. This evidence concerns the gene NAGS and gastric adenocarcinoma.